Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 750 of 2529 entries
View as:

A Study of LCL161 in Combination With Weekly Paclitaxel in Adult Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01240655 Org: User:
Start: 04/30/11 End: 01/31/15 Due: 01/31/16

Long-term Follow-up of Fingolimod Phase II Study Patients

Phase: N/A Priority: Normal
NCT ID: NCT02307838 Org: User:
Start: 06/30/14 End: 12/31/15 Due: 12/31/16

A Study Comparing AIN457 to Placebo in Subjects With a Diagnosis of Moderate to Severe Stable Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT00669916 Org: User:
Start: 02/28/07 End: 11/30/07 Due: 11/30/08

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

Phase: N/A Priority: Normal
NCT ID: NCT03589885 Org: User:
Start: 12/19/18 End: 08/05/20 Due: 08/05/21

Efficacy and Safety of Everolimus (RAD001) Compared to Placebo in Patients With Advanced Neuroendocrine Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00510068 Org: User:
Start: 07/31/07 End: 03/31/14 Due: 03/31/15

Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02180217 Org: User:
Start: 10/06/14 End: 12/04/19 Due: 12/04/20

Safety and Efficacy of AQW051 in L-dopa Induced Dyskinesias in Patients With Parkinson's Disease

Phase: N/A Priority: Normal
NCT ID: NCT01474421 Org: User:
Start: 09/15/11 End: 02/21/13 Due: 02/21/14

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of VAY736 in Rheumatoid Arthritis Patients

Phase: N/A Priority: Normal
NCT ID: NCT02675803 Org: User:
Start: 12/20/10 End: 01/22/18 Due: 01/22/19

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.

Phase: N/A Priority: Normal
NCT ID: NCT05838768 Org: User:
Start: 06/27/23 End: 05/30/29 Due: 05/30/30

Ceritinib Rare Indications Study in ALK+ Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02465528 Org: User:
Start: 05/06/16 End: 08/20/18 Due: 08/20/19

A 12-week, Multicenter, Safety and Dose-ranging Study of 3 Oral Doses of TCH346 in Patients With Amyotrophic Lateral Sclerosis

Phase: N/A Priority: Normal
NCT ID: NCT00036413 Org: User:
Start: 01/31/02 End: 10/31/02 Due: 10/31/03

Observational Study to Evaluate Fluid Resolution and Effectiveness in Patients Receiving Beovu in Neovascular Age-related Macular Degeneration and Visual Impairment Due to Diabetic Macular Edema

Phase: N/A Priority: Normal
NCT ID: NCT04543331 Org: User:
Start: 11/05/20 End: 12/20/25 Due: 12/20/26

A Study to Identify an Optimal Dose of QCZ484 in Mild to Moderate Hypertensive Patients

Phase: N/A Priority: Normal
NCT ID: NCT06857955 Org: User:
Start: 03/26/25 End: 12/21/27 Due: 12/21/28

Patterns of Inclisiran Use in the Real World: An Analysis of US Databases

Phase: N/A Priority: Normal
NCT ID: NCT07023445 Org: User:
Start: 01/20/23 End: 06/28/24 Due: 06/28/25

Study of Enteric-coated Mycophenolate Sodium (EC-MPS) With Steroid Withdrawal vs EC-MPS With Standard Steroid Regimen in de Novo Renal Transplant Recipients.

Phase: N/A Priority: Normal
NCT ID: NCT00238992 Org: User:
Start: 12/31/02 End: - Due: -

A Study to Evaluate CSJ148 in Pregnant Women With Primary HCMV Infection

Phase: N/A Priority: Normal
NCT ID: NCT03369912 Org: User:
Start: 10/23/18 End: 11/15/22 Due: 11/15/23

Combination Study of Deferasirox and Erythropoietin in Patients With Low- and Int-1-risk Myelodysplastic Syndrome.

Phase: N/A Priority: Normal
NCT ID: NCT01868477 Org: User:
Start: 01/28/14 End: 04/05/17 Due: 04/05/18

A Dose Range Finding Study With Open-Label Extension to Evaluate the Safety of Oral LMI070/Branaplam in Early Manifest Huntington's Disease

Phase: N/A Priority: Normal
NCT ID: NCT05111249 Org: User:
Start: 12/08/21 End: 10/27/23 Due: 10/27/24

Efficacy and Safety of Deferasirox in Patients With Myelodysplastic Syndrome and Transfusion-dependent Iron Overload

Phase: N/A Priority: Normal
NCT ID: NCT00481143 Org: User:
Start: 05/31/07 End: - Due: -

Vildagliptin add-on to Glimepiride Versus Placebo Added to Glimepiride in Type 2 Diabetes

Phase: N/A Priority: Normal
NCT ID: NCT01357252 Org: User:
Start: 04/30/11 End: 01/31/13 Due: 01/31/14

3-year Follow-up Study to Assess the Viral Activity in Hepatitis C Patients Who Failed Feeder DEB025/Alisporivir Study

Phase: N/A Priority: Normal
NCT ID: NCT02465203 Org: User:
Start: 09/06/12 End: 01/23/14 Due: 01/23/15

Study of Afuresertib Monotherapy in Japanese Relapsed Multiple Myeloma Patients

Phase: N/A Priority: Normal
NCT ID: NCT02177682 Org: User:
Start: 08/13/14 End: 08/14/19 Due: 08/14/20

Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis

Phase: N/A Priority: Normal
NCT ID: NCT00332696 Org: User:
Start: 09/30/05 End: 09/30/08 Due: 09/30/09

A 24-week, Multicenter, proSpective stUdy to Evaluate the PASI 90 Clinical Response Rate and the Safety PRofile of sEcukinuMab 300 mg in Cw6-negativE and Cw6-positive Patients With Moderate to Severe Chronic Plaque-type Psoriasis (SUPREME)

Phase: N/A Priority: Normal
NCT ID: NCT02394561 Org: User:
Start: 04/10/15 End: 06/08/17 Due: 06/08/18

Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study

Phase: N/A Priority: Normal
NCT ID: NCT00940602 Org: User:
Start: 03/22/10 End: 02/27/18 Due: 02/27/19